These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 4611534)
1. Neuraminidase treated cells and their role in cancer immunotherapy. Simmons RL; Rios A Birth Defects Orig Artic Ser; 1973 Mar; 9(2):223-8. PubMed ID: 4611534 [No Abstract] [Full Text] [Related]
2. Neuraminidase and concanavalin A in the experimental immunotherapy of cancer. Simmons RL; Rios A Johns Hopkins Med J Suppl; 1974; 3():75-84. PubMed ID: 4536589 [No Abstract] [Full Text] [Related]
3. Comparative immunotherapeutic effect of concanavalin A and neuraminidase-treated cancer cells. Simmons RL; Rios A Transplant Proc; 1975 Jun; 7(2):247-51. PubMed ID: 1129845 [No Abstract] [Full Text] [Related]
4. Comparative effect of Mycobacterium bovis- and neuraminidase-treated tumor cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice. Rios A; Simmons RL Cancer Res; 1972 Jan; 32(1):16-21. PubMed ID: 4550256 [No Abstract] [Full Text] [Related]
5. Comparative and combined effect of BCG and neuraminidase in experimental immunotherapy. Simmons RL; Rios A Natl Cancer Inst Monogr; 1973 Dec; 39():57-68. PubMed ID: 4595327 [No Abstract] [Full Text] [Related]
6. Immunospecific regression of methylcholanthrene fibrosarcoma using neuraminidase. 3. Synergistic effect of BCG and neuraminidase treated tumor cells. Simmons RL; Rios A Ann Surg; 1972 Aug; 176(2):188-94. PubMed ID: 4562008 [No Abstract] [Full Text] [Related]
7. Experimental and clinical trials with BCG immunotherapy. Sparks FC; Silverstein MJ; Hunt JS; O'Connell TX; Lee YT; Pilch YH; Haskell CM; Morton DL Johns Hopkins Med J Suppl; 1974; 3():103-20. PubMed ID: 4609024 [No Abstract] [Full Text] [Related]
8. Immunotherapy with neuraminidase-treated tumor cells after radiotherapy. Song CW; Levitt SH Radiat Res; 1975 Dec; 64(3):485-91. PubMed ID: 1197655 [No Abstract] [Full Text] [Related]
9. Experimental cancer immunotherapy using a neuraminidase-treated non-viable frozen tumor vaccine. Rios A; Simmons RL Surgery; 1974 Apr; 75(4):503-7. PubMed ID: 4840798 [No Abstract] [Full Text] [Related]
10. Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells. Rios A; Simmons RL Int J Cancer; 1974 Jan; 13(1):71-81. PubMed ID: 4818273 [No Abstract] [Full Text] [Related]
11. Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas. Simmons RL; Rios A J Immunol; 1973 Dec; 111(6):1820-5. PubMed ID: 4750868 [No Abstract] [Full Text] [Related]
12. Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas. Spence RJ; Simon RM; Baker AR J Natl Cancer Inst; 1978 Feb; 60(2):451-9. PubMed ID: 621758 [TBL] [Abstract][Full Text] [Related]
13. Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice. Simmons RL; Rios A; Ray PK; Lundgren G J Natl Cancer Inst; 1971 Nov; 47(5):1087-94. PubMed ID: 5123336 [No Abstract] [Full Text] [Related]
14. Radiation therapy and immunotherapy: the value of immunotherapy in the control of local and regional cancer. Cancer; 1976 Apr; 37(4 Suppl):2108-19. PubMed ID: 769945 [No Abstract] [Full Text] [Related]
16. Effect of inoculation with neuraminidase-treated tumor cells on macrophage cytotoxicity in vitro. Alley CD; Snodgrass MJ Cancer Res; 1978 Aug; 38(8):2332-8. PubMed ID: 667829 [No Abstract] [Full Text] [Related]
17. Modified tumor cells in the immunotherapy of solid mammary tumors. Simmons RL; Rios A; Trites P Med Clin North Am; 1976 May; 60(3):551-65. PubMed ID: 1271892 [No Abstract] [Full Text] [Related]
18. Cell surface modification in the treatment of experimental cancer: neuraminidase or concanavalin A. Simmons RL; Rios A Cancer; 1974 Oct; 34(4 Suppl):suppl:1541-7. PubMed ID: 4138077 [No Abstract] [Full Text] [Related]
19. Immunospecific regression of various syngeneic mouse tumors in response to neuraminidase-treated tumor cells. Rios A; Simmons RL J Natl Cancer Inst; 1973 Aug; 51(2):637-44. PubMed ID: 4765377 [No Abstract] [Full Text] [Related]
20. The development of cellular immunity to tumor cells. Cerilli J; Smith MC Surg Gynecol Obstet; 1972 May; 134(5):739-45. PubMed ID: 5064081 [No Abstract] [Full Text] [Related] [Next] [New Search]